The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies

Suhrud Pathak,Rishi Nadar,Shannon Kim,Keyi Liu,Manoj Govindarajulu,Preston Cook,Courtney S. Watts Alexander,Muralikrishnan Dhanasekaran,Timothy Moore
DOI: https://doi.org/10.3390/ijms25020853
IF: 5.6
2024-01-11
International Journal of Molecular Sciences
Abstract:As the kynurenine pathway's links to inflammation, the immune system, and neurological disorders became more apparent, it attracted more and more attention. It is the main pathway through which the liver breaks down Tryptophan and the initial step in the creation of nicotinamide adenine dinucleotide (NAD+) in mammals. Immune system activation and the buildup of potentially neurotoxic substances can result from the dysregulation or overactivation of this pathway. Therefore, it is not shocking that kynurenines have been linked to neurological conditions (Depression, Parkinson's, Alzheimer's, Huntington's Disease, Schizophrenia, and cognitive deficits) in relation to inflammation. Nevertheless, preclinical research has demonstrated that kynurenines are essential components of the behavioral analogs of depression and schizophrenia-like cognitive deficits in addition to mediators associated with neurological pathologies due to their neuromodulatory qualities. Neurodegenerative diseases have been extensively associated with neuroactive metabolites of the kynurenine pathway (KP) of tryptophan breakdown. In addition to being a necessary amino acid for protein synthesis, Tryptophan is also transformed into the important neurotransmitters tryptamine and serotonin in higher eukaryotes. In this article, a summary of the KP, its function in neurodegeneration, and the approaches being used currently to target the route therapeutically are discussed.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper attempts to explore the effects of kynurenine metabolites in the tryptophan metabolic pathway on neurodegenerative diseases. Specifically, the article focuses on the role of the kynurenine pathway (KP) in inflammation, the immune system, and neurodegenerative diseases (such as depression, Parkinson's disease, Alzheimer's disease, Huntington's disease, schizophrenia, and cognitive impairment). The study points out that the dysregulation or over - activation of KP may lead to the activation of the immune system and the accumulation of potentially neurotoxic substances, and these factors are closely related to the occurrence and development of neurodegenerative diseases. Therefore, by regulating the metabolic process of KP, new strategies and targets may be provided for the treatment of these diseases. The paper describes in detail the metabolic pathway of KP and its specific influence mechanisms in neurodegenerative diseases, including the generation of neurotoxic metabolites such as 3 - hydroxykynurenine (3 - HK) and quinolinic acid (QA), as well as the production of metabolites with neuroprotective effects such as kynurenic acid (KYNA). In addition, the article also discusses the possibility of KP metabolites as potential biomarkers and the application prospects of drug - regulation methods targeting KP in the treatment of neurodegenerative diseases.